KYTX
NASDAQ · Biotechnology
Kyverna Therapeutics Inc
$7.07
-0.44 (-5.86%)
Open$7.50
Previous Close$7.51
Day High$7.54
Day Low$6.99
52W High$13.67
52W Low$3.95
Volume—
Avg Volume702.9K
Market Cap440.94M
P/E Ratio—
EPS$-2.94
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+15.4% upside
Current
$7.07
$7.07
Target
$8.16
$8.16
$5.68
$8.16 avg
$10.96
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.52M | 81.06M | 62.85M |
| Net Income | -14,424,701 | -12,557,463 | -9,873,224 |
| Profit Margin | -18.6% | -15.5% | -15.7% |
| EBITDA | -20,391,428 | -20,108,436 | -16,996,352 |
| Free Cash Flow | -5,835,314 | -8,946,067 | -4,753,485 |
| Rev Growth | +5.4% | +22.1% | -7.0% |
| Debt/Equity | 0.25 | 0.20 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |